Physician profile
Danielle Johnson
NPI 1891339032
$13,296.27
in general payments reported to CMS, 2019-2025
22 companies · $8,743 in 2025
The $8,743 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $802 · 2023: $1,001 · 2024: $2,750 · 2025: $8,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,062 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,338 · Education: $71.76 · Travel and Lodging: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,061.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,338.00 |
| Education | $71.76 |
| Travel and Lodging | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $6,662.82 | 2022-2025 | Tremfya |
| Abbvie INC. | $2,513.36 | 2022-2025 | |
| Galderma Laboratories, L.P. | $693.94 | 2022-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $613.69 | 2022-2025 | Adbry, Anzupgo |
| Amgen INC. | $608.19 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $366.70 | 2022-2025 | Dupixent |
| Genzyme Corporation | $306.14 | 2023-2025 | |
| Incyte Corporation | $304.41 | 2022-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $281.90 | 2024-2025 | Tremfya |
| Pfizer INC. | $208.06 | 2022-2024 | |
| Gilead Sciences, INC. | $121.18 | 2024 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $117.07 | 2025 | |
| Sun Pharmaceutical Industries INC. | $116.68 | 2022-2025 | |
| Ucb, INC. | $115.01 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $81.84 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $51.92 | 2024 | Taltz |
| Verrica Pharmaceuticals INC. | $37.17 | 2024 | Ycanth |
| Organon LLC | $25.73 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.53 | 2024 | Cabtreo |
| Biofrontera INC. | $17.68 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Glaxosmithkline, LLC. | $17.47 | 2024 | Bexsero, Pediarix, Rotarix |
| Genentech, INC. | $14.78 | 2023 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.